Randomized Controlled Trial Comparing Low Dose Tadalafil Versus Solifenacin For Management of Overactive Bladder in Women: Multicenter Egyptian National Study

Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexFemale
Age18-75
SponsorMansoura University

About this trial

Researchers are studying two medicines to see which works better for women with overactive bladder (OAB). OAB causes sudden urges to urinate, frequent bathroom trips, and sometimes leakage.

Women who join the study will be randomly placed into one of two groups:

One group will take tadalafil (5 mg), a medicine taken once a day.

The other group will take solifenacin (5 mg), a common treatment for OAB, also taken once a day.

The study will last 12 weeks. Participants will keep a bladder diary, answer short questionnaires, and have simple urine flow and bladder tests at several visits.

The main goal is to find out which medicine lowers OAB symptoms more, such as urgency and frequent urination. Researchers will also look at quality of life, bladder function, and side effects.

Women aged 18 to 75 years with OAB symptoms for at least 3 months may be able to take part.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

OAB symptoms persisting for ≥3 months

OAB Symptom Score (OABSS) > 5 and urgency sub-score of OABSS ≥ 2

Ability and willingness to provide informed consent.

Disqualifiers

Active urinary tract infection.

Stress urinary incontinence (SUI) as primary diagnosis, or mixed urinary incontinence with predominant SUI

Pelvic organ prolapse stage ≥II according to POP-Q system.

History of pelvic radiation.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Tadalafil 5 mg

    Drug

    Tadalafil 5 mg orally once daily for the duration of 12 weeks

  • Solifenacin 5mg

    Drug

    solifenacin succinate 5 mg orally once daily for the duration of 12 weeks

Treatment groups

480 Participants
are divided into 2 treatment groups
Group A: Group 1, Low dose Tadalafil groupExperimental treatment 1 intervention
Group B: Group 2: Solifenacin GroupActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Overactive Bladder Symptom Score percentage reduction

self administered questionnaire with minimum score of 0 and maximum score of 15, higher score means worse symptoms. Three points reduction in the total OABSS is determined as the minimal threshold for a meaningful change

Time frame
from enrollment to 12 weeks

Secondary outcomes

1

Changes in frequnecy episodes in three-day voiding diary

Changes in the mean number of voiding episodes per days as measure by a self administered three-day urinary diary

Time frame
from enrollment to follow up visits at 4,8 and 12 weeks
2

changes in International Consultation on Incontinence Questionnaire- Urinary Incontinence-Short Form (ICIQ-UI-SF) score

self administered questionnaire with minimum score of 0 and maximum score of 21, the higher score, the worse the symptoms

Time frame
from enrollment to follow up visits at 4,8 and 12 weeks
3

changes in Overactive bladder quality of life questionnaire (ICIQ-OABqol)

elf administered questionnaire with minimum score of 25 and maximum score of 160 , higher score indicated worse effect on the quality of life

Time frame
All follow up visits at 4, 8, and 12 weeks
4

Changes in number of nocturia episodes on three-day urinary diary

changes in the mean number of nocturia episodes per night(waking up in the middle of the night to void) as measured by a self-administered three-day voiding diary

Time frame
from enrollment to follow up visits at 4,8 and 12 weeks

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Mansoura University

Lead sponsor

Cairo University

Collaborator

Ain Shams University

Collaborator

Alexandria University

Collaborator

Zagazig University

Collaborator

Tanta University

Collaborator

Menoufia University

Collaborator

Assiut University

Collaborator

Sohag University

Collaborator

South Valley University

Collaborator

Beni-Suef University

Collaborator

Minia University

Collaborator

Aswan University

Collaborator